Belgium released a statement on Wednesday that it was suspending the use of Johnson & Johnson’s Janssen vaccinations for people under the age of 41, following the first death in Europe from side-effects associated with the shot.
Belgium’s health minister and seven regional counterparts said in a statement that, “The Inter-ministerial conference has decided to temporarily administer Janssen’s vaccine to the general population from the age of 41 years, pending a more detailed benefit-risk analysis by the EMA (European Medicines Agency)”.
The EMA said that it was reviewing the “first fatal report” of a 37-year-old woman in Belgium who had suffered from a blood clot with low platelets, a condition previously associated with the shot.
It also added that it had asked the US drugmaker to carry out a series of additional research to assess the possible link between the shot and the rare clotting condition.
ALSO READ: Does COVID really affect your heart?